Abstract
Bone Metastases Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “Bone Metastases Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global bone metastases therapeutics market. The report identifies the key trends shaping and driving the global bone metastases therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global bone metastases therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimates that the global bone metastases therapeutics market was valued at $1,425m in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 12% over the next seven years to reach $6,390m by 2017. Although the drug pipeline for the treatment of bone metastases is strong, the launch of Amgen’s Xgeva in early 2010, which is another breakthrough for bone metastases patients, is the primary driver for increased market growth. The market remains well-served with the current marketed products, most of which are significantly efficacious in their respective target areas. Essentially, the global bone metastases market is heading towards a phase of continuous growth, leveraging the current opportunities.
Scope
The report provides information on the key drivers and challenges of the bone metastases market. Its scope includes -
• Annualized global bone metastases market revenues data from 2005 to 2010, forecast for seven years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as as cathepsin K inhibitors, TGF (transforming growth factor) inhibitors, lysophosphatidic acid (LPA), G-protein-coupled receptors (GPCRs) inhibitors, integrin receptor antagonist, ATPase-dependent hydrogen ion inhibitor, Alpha-radiopharmaceutical, and a weekly oral zoledronic acid.
• Analysis of the current and future competition in the global bone metastases market. Key market players covered are Novartis AG, Amgen, F. Hoffmann-La Roche Ltd, Bayer-Algeta, Merrion Pharmaceuticals Plc., Ablynx, Genta Incorporated, Galapagos NV, Catena Pharmaceuticals, Inc, Digna Biotech, S.L., Medivir AB, and Amura Holdings.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the bone metastases therapeutics market.
• Analysis of key recent licensing and partnership agreements in bone metastases therapeutics market.
Reasons To Buy
The report will enhance your decision making capability. It will allow you to -
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global bone metastases therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global bone metastases therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global bone metastases therapeutics market landscape? – Identify, understand and capitalize.
Companies Mentioned
Novartis AG
Amgen Inc.
Bayer AG
Algeta ASA
Merrion Pharmaceuticals Plc
Table of Contents
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Bone Metastasis Therapeutics: Introduction
2.1 Disease Overview
2.2 Epidemiology
2.3 Etiology and Pathophysiology
2.4 Signs and Symptoms
2.5 Diagnosis
2.6 Treatment and Management Pattern: 14
2.6.1 Systemic Therapy
2.6.2 External Beam Radiation Therapy
2.7 GlobalData Pipeline Report Guidance
3 Bone Metastases Therapeutics: Market Characterization
3.1 Bone Metastases Therapeutics Market Size (2005-2010) – Global
3.2 Bone Metastases Therapeutics Market Forecast (2010-2017) – Global
3.3 Bone Metastases Therapeutics Market Size (2005-2010) – The US
3.4 Bone Metastases Therapeutics Market Forecasts (2010-2017) – The US
3.5 Bone Metastases Therapeutics Market Size (2005-2010) – France
3.6 Bone Metastases Therapeutics Market Forecasts (2010-2017) – France
3.7 Bone Metastases Therapeutics Market Size (2005-2010) – Germany
3.8 Bone Metastases Therapeutics Market Forecasts (2010-2017) – Germany
3.9 Bone Metastases Therapeutics Market Size (2005-2010) – Italy
3.10 Bone Metastases Therapeutics Market Forecast (2010-2017) – Italy
3.11 Bone Metastases Therapeutics Market Size (2005-2010) – Spain
3.12 Bone Metastases Therapeutics Market Forecasts (2010-2017) – Spain
3.13 Bone Metastases Therapeutics Market Size (2005-2010) – The UK
3.14 Bone Metastases Therapeutics Market Forecasts (2010-2017) – The UK
3.15 Bone Metastases Therapeutics Market Size (2005-2010) – Japan
3.16 Bone Metastases Therapeutics Market Forecasts (2010-2017) – Japan
3.17 Drivers and Barriers for the Bone Metastases Therapeutics Market
3.17.1 Drivers for the Bone Metastases Therapeutics Market
3.17.2 Barriers for the Bone Metastases Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway
4 Bone Metastases Therapeutics: Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the Bone Metastases Therapeutics Market
4.3.1 Zometa (zoledronic acid)
4.3.2 Xgeva (denosumab)
4.3.3 Bondronat (ibandronic acid)
4.4 Key Takeaway
5 Bone Metastases Therapeutics: Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Bone Metastases Therapeutics – Pipeline Analysis by Phases of Development
5.3.1 Bone Metastases Therapeutics – Filed Products
5.3.2 Bone Metastases Therapeutics – Phase III Pipeline
5.3.3 Bone Metastases Therapeutics – Phase II Pipeline
5.3.4 Bone Metastases Therapeutics – Phase I Pipeline
5.3.5 Bone Metastases Therapeutics – Preclinical Pipeline
5.3.6 Technology Trends Analytic Framework
5.4 Bone Metastases Therapeutics Market – Clinical Pipeline by Mechanism of Action
5.5 Bone Metastases Therapeutics – Promising Drugs Under Clinical Development
5.6 Molecule Profile for Promising Drugs Under Clinical Development
5.6.1 Alpharadin (radium-223 chloride)
5.6.2 Orazol (Zoledronic acid)
5.7 Key Takeaway
6 Bone Metastases Therapeutics: Clinical Trials Mapping
6.1 Clinical Trials by Country (the US, EU and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in Bone Metastases Therapeutics Clinical Trials
7 Bone Metastases Therapeutics: Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Bone Metastases Therapeutics: Implications for Future Market Competition
8 Bone Metastases Therapeutics: Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Novartis AG
8.2.2 Amgen Inc.
8.2.3 Bayer AG
8.2.4 Algeta ASA
8.2.5 Merrion Pharmaceuticals Plc
8.2.6 Other Companies in the Bone Metastases Therapeutics Market
9 Bone Metastases Therapeutics: Licensing and Partnership Deals
10 Bone Metastases Therapeutics: Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography
List of Tables
1.1 List of Tables
Table 1: Metastatic Bone Disease is Prevalent in Many Types of Cancer
Table 2: Prevalence of Bone Metastases in Different Cancer Types, 2010
Table 3: Bone Metastases Therapeutics Market, Global, Revenue ($m), 2005–2010
Table 4: Bone Metastases Therapeutics Market, Global, Forecast ($m), 2010–2017
Table 5: Bone Metastases Therapeutics Market, France, Revenue ($m), 2005–2010
Table 6: Bone Metastases Therapeutics Market, France, Forecasts ($m), 2010–2017
Table 7: Bone Metastases Therapeutics Market, Germany, Revenue ($m), 2005–2010
Table 8: Bone Metastases Therapeutics Market, Germany, Forecasts ($m), 2010–2017
Table 9: Bone Metastases Therapeutics Market, Italy, Revenue ($m), 2005–2010
Table 10: Bone Metastases Therapeutics Market, Italy, Forecasts ($m), 2010–2017
Table 11: Bone Metastases Therapeutics Market, Spain, Revenue ($m), 2005–2010
Table 12: Bone Metastases Therapeutics Market, Spain, Forecasts ($m), 2010–2017
Table 13: Bone Metastases Therapeutics Market, The UK, Revenue ($m), 2005–2010
Table 14: Bone Metastases Therapeutics Market, The UK, Forecasts ($m), 2010–2017
Table 15: Bone Metastases Therapeutics Market, Japan, Revenue ($m), 2005–2010
Table 16: Bone Metastases Therapeutics Market, Japan, Forecasts ($m), 2010–2017
Table 17: Bone Metastases Therapeutics – Filed Products, 2010
Table 18: Bone Metastases Therapeutics – Phase III Pipeline, 2010
Table 19: Bone Metastases Therapeutics – Phase II Pipeline, 2010
Table 20: Bone Metastases Therapeutics – Phase I Pipeline, 2010
Table 21: Bone Metastases Therapeutics – Preclinical Pipeline, 2010
Table 22: Bone Metastases Therapeutics – Most Promising Drugs Under Clinical Development, 2010
Table 23: Bone Metastases Therapeutics – Clinical Trials by Country, 2011
Table 24: Bone Metastases Therapeutics - Clinical Trials by Phase, 2011
Table 25: Bone Metastases Therapeutics - Clinical Trials by Status, 2011
Table 26: Bone Metastases Therapeutics - Clinical Trials by Prominent Sponsors, 2011
Table 27: Bone Metastases Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 28: Novartis – Oncology Pipeline, 2010
Table 29: Novartis Deals, 2009-2010
Table 30: Amgen Inc. – Oncology, Pipeline, 2010
Table 31: Amgen Inc. – Bone Metastases, Pipeline, 2010
Table 32: Amgen Inc. Deals, 2009-2010
Table 33: Bayer AG – Oncology Pipeline, 2010
Table 34: Bayer AG Deals, 2009-2010
Table 35: Algeta ASA Pharmaceuticals – Oncology, Pipeline, 2010
Table 36: Algeta ASA Pharmaceuticals – Bone Metastases, Pipeline, 2010
Table 37: Algeta ASA Deals, 2009-2010
Table 38: Merrion Pharmaceuticals – Oncology Pipeline, 2010
Table 39: Merrion Pharmaceuticals – Oncology Pipeline, 2010
Table 40: Merrion AG Deals, 2009-2010
Table 41: Bone Metastases Pain Therapeutics Market – Future Players
Table 42: Bone Metastases Therapeutics, Global, Deals
List of Figures
1.2 List of Figures
Figure 1: (a) Osteolytic lesions; (b) Osteoblastic lesion
Figure 2: Mechanism of Tumor Metastasis to Bone
Figure 3: Prevalence of Skeletal-Related Events in Patients with Metastatic Bone Disease not Treated with Bisphosphonates
Figure 4: Diagnosis of Bone Metastases
Figure 5: Algorithm for Imaging for Cancer Patients in the US
Figure 6: Bone Metastases Therapeutics Market, Global, Revenue ($m), 2005–2010
Figure 7: Bone Metastases Therapeutics Market, Global, Forecast ($m), 2010–2017
Figure 8: Bone Metastases Therapeutics Market, The US, Revenue ($m), 2005–2010
Figure 9: Bone Metastases Therapeutics Market, The US, Forecasts ($m), 2010–2017
Figure 10: Bone Metastases Therapeutics Market, France, Revenue ($m), 2005–2010
Figure 11: Bone Metastases Therapeutics Market, France, Forecasts ($m), 2010–2017
Figure 12: Bone Metastases Therapeutics Market, Germany, Revenue ($m), 2005–2010
Figure 13: Bone Metastases Therapeutics Market, Germany, Forecasts ($m), 2010–2017
Figure 14: Bone Metastases Therapeutics Market, Italy, Revenue ($m), 2005–2010
Figure 15: Bone Metastases Therapeutics Market, Italy, Forecasts ($m), 2010–2017
Figure 16: Bone Metastases Therapeutics Market, Spain, Revenue ($m), 2005–2010
Figure 17: Bone Metastases Therapeutics Market, Spain, Forecasts ($m), 2010–2017
Figure 18: Bone Metastases Therapeutics Market, The UK, Revenue ($m), 2005–2010
Figure 19: Bone Metastases Therapeutics Market, The UK, Forecasts ($m), 2010–2017
Figure 20: Bone Metastases Therapeutics Market, Japan, Revenue ($m), 2005–2010
Figure 21: Bone Metastases Therapeutics Market, Japan, Forecasts ($m), 2010–2017
Figure 22: Opportunity and Unmet Need in the Bone Metastases Therapeutics Market, 2010
Figure 23: Bone Metastases Therapeutics – Strategic Competitor Assessment, 2010
Figure 24: Bone Metastases Therapeutics – Pipeline by Phase of Development, 2011
Figure 25: Bone Metastases Therapeutics – Technology Trends Analytics Framework, 2011
Figure 26: Bone Metastases Therapeutics – Technology Trends Analytics Framework – Description, 2011
Figure 27: Bone Metastases Therapeutics – Pipeline by Mechanism of Action, 2010
Figure 28: Bone Metastases Therapeutics – Clinical Trials by Country, 2011
Figure 29: Bone Metastases Therapeutics - Clinical Trials by Phase, 2011
Figure 30: Bone Metastases Therapeutics - Clinical Trials by Status, 2011
Figure 31: Bone Metastases Therapeutics - Clinical Trials by Overall Sponsors, 2011
Figure 32: Bone Metastases Therapeutics - Clinical Trials by Prominent Sponsors, 2011
Figure 33: Bone Metastases Therapeutics - Top Companies Participating in Clinical Trials, 2011
Figure 34: Bone Metastases Therapeutics Market, Drivers and Restraints, 2011
Figure 35: Implications for Future Market Competition in Bone Metastases, 2011
Figure 36: Bone Metastases Therapeutics – Pipeline by Company, 2011
Figure 37: GlobalData Market Forecasting Model
